Robatumumab
Robatumumab (proposed INN; also known as SCH 717454 and MK-7454) is a monoclonal antibody and an antineoplastic by Merck and Schering-Plough. It binds to CD221, the insulin-like growth factor 1 receptor.[1]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CD221 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6418H9960N1732O1992S42 |
Molar mass | 144602.93 g·mol−1 |
|
Phase 2 clinical trials in patients with colorectal cancer, osteosarcoma and Ewing's sarcoma are complete.[2][3] Merck has since discontinued development.[4]
References
- "robatumumab", p. 337 in: Quality Assurance and Safety of Medicines (2008). Encrenaz, C. (ed.). "Proposed International Nonproprietary Names: List 100" (PDF). WHO Drug Information. 22 (4): 311–67.
- Anderson, Peter M.; Bielack, Stefan S.; Gorlick, Richard G.; Skubitz, Keith; Daw, Najat C.; Herzog, Cynthia E.; Monge, Odd R.; Lassaletta, Alvaro; Boldrini, Erica; Pápai, Zsuzanna; Rubino, Joseph; Pathiraja, Kumudu; Hille, Darcy A.; Ayers, Mark; Yao, Siu-Long; Nebozhyn, Michael; Lu, Brian; Mauro, David (2016). "A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma". Pediatric Blood & Cancer. 63 (10): 1761–70. doi:10.1002/pbc.26087. PMC 5129487. PMID 27362300.
- Clinical trial number NCT00551213 for "A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)" at ClinicalTrials.gov
- http://adisinsight.springer.com/drugs/800027277
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.